Bedrijfsoverzicht
Metagenomi Therapeutics, Inc. is an in vivo genome editing company that specializes in developing curative genetic medicines within the United States market. The organization operates within the healthcare sector and specifically functions in the biotechnology industry, focusing on innovative therapeutic solutions for genetic conditions. The company currently employs a workforce of 119 individuals and maintains a market capitalization of $51.92M, while generating annual revenue of $25.21M. These financial figures indicate that Metagenomi Therapeutics operates as a micro-cap entity with a revenue scale that suggests it is still in a developmental phase typical for biotechnology firms focused on high-risk, high-reward research programs. The specific business focus involves the lead development program MGX-001, which is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. This operational scope defines the company's primary value proposition and its strategic positioning within the specialized field of hemophilia treatments. The combination of a modest market cap and a specialized product pipeline highlights the company's potential for significant value creation if its clinical programs achieve regulatory approval and commercial success.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $25.21M, yet it recorded a net income of $-87,868,000 and an EBITDA of $-90,696,000 during the same period. The substantial gap between the $25.21M revenue and the significant net loss of $87.87M reveals a cost structure heavily weighted towards research and development expenses, which is characteristic of biotechnology companies in the pre-revenue or early commercialization stages. Free cash flow stood at $-53,307,124, indicating that the company is consuming cash to fund its operations and development activities rather than generating surplus liquidity from its current business model. Gross margin was reported at -274.6%, operating margin at -623.0%, and profit margin at 0.0%, figures that collectively indicate that costs associated with delivering services or products currently exceed the direct revenue generated on a per-unit basis. Despite these negative margins, the company holds $160.80M in cash against $40.66M in debt, resulting in a debt-to-equity ratio of 25.64. The current ratio of 7.22 suggests that the company possesses a strong position in terms of short-term liquidity, as its current assets significantly exceed its current liabilities. Return on equity is -44.7% and return on assets is -22.0%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, which is expected for a company investing heavily in long-term drug development projects.
Waarderingsbeoordeling
The P/E ratio (TTM) is listed as N/A due to the company's lack of positive earnings, while the forward P/E is -0.83, implying that the market expects earnings to remain negative or that valuation is being driven by assets rather than current profitability. The price-to-book ratio stands at 0.33, indicating that the company is trading at a discount to its book value, which often reflects investor caution regarding the risks associated with the biotechnology sector and the potential dilution of existing equity. The price-to-sales ratio is 2.06 and the EV/EBITDA is 0.75, suggesting that the market values the company based on its revenue potential and asset base rather than earnings power, a common valuation approach for pre-profitable biotech firms. The stock has traded within a 52-week range with a high of $3.95 and a low of $1.25, meaning the current trading price sits below the 52-week high but above the 52-week low. The beta value of 0.57 indicates that the stock's price volatility is lower than that of the broader market, suggesting it may be less sensitive to general market fluctuations compared to large-cap equities. These valuation metrics combined suggest that the company is priced for survival and future milestone achievements rather than current financial performance.
Growth & Income
Revenue growth year-over-year declined by -59.3%, while earnings growth is N/A due to the absence of earnings in the prior period for comparison. The decline in revenue suggests a contraction in sales, potentially due to the early stage of commercialization or specific market conditions affecting the lead product. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, which means the company reinvests all available resources and cash reserves into research, development, and operational expansion rather than distributing income to shareholders. The overall growth and income profile is characterized by significant revenue contraction and negative earnings, reflecting the strategic choice to prioritize long-term asset development over short-term financial returns. The company's financial strategy focuses on leveraging its cash reserves to push its genome editing programs forward, accepting the current lack of income generation to achieve potential future market penetration.